Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Merck Pepcid AC first chewable H2 is latest twist in stomach remedy market.

This article was originally published in The Tan Sheet

Executive Summary

J&J/MERCK PEPCID AC CHEWABLE TABLETS "APPROVABLE" at FDA as of Dec. 19 under NDA 20-801. The NDA is separate from the original application for the OTC H2 antagonist for prevention and treatment of heartburn that was approved in April 1995. If there are no glitches and the new NDA is approved, Pepcid AC would be the first chewable H2 antagonist on the market. J&J/Merck's interest in capturing market share by introducing a new delivery system reflects the rapid maturation of H2 antagonists as the brand name marketers get ready to compete with private label products such as those from Perrigo, Granutec and PFI ("The Tan Sheet" Nov. 17, 1997, p. 12). The approvable NDA presumably covers 10 mg famotidine chewable tablets.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087953

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel